Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES TOBII IN CONNECTION WITH ACQUISITION OF DYNAVOX
Mandate

VINGE ADVISES TOBII IN CONNECTION WITH ACQUISITION OF DYNAVOX

May 23, 2014

Vinge has advised Tobii Technology in connection with its acquisition of the US company, Dynavox Systems LLC. Tobii Technology is the global leader within eye tracking. DynaVox is the leading provider of augmentative and alternative communication products and speech generating devices for people with cognitive communication difficulties, e.g. autism, aphasia and who suffer from other communication challenges.

Vinge’s team consisted of responsible partner Johan Winnerblad together with, among others, associate Matthias Pannier. Associate Louise Brorsson Salomon provided acquisition financing advice.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026